Minerva Biotechnologies Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Private

  • Employees
  • 17

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $4.51M

  • Investors
  • 3

Minerva Biotechnologies General Information

Description

Developer of immunotherapies and drugs designed to target solid tumors and prevent cancer metastasis. The company's drugs generate human naïve state-induced pluripotent stem cells that target the MUC1 growth factor receptor, enabling researchers to design simple colorimetric assays to detect a broad array of antibody-antigen, protein-protein, and protein-ligand interactions.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 68 Cummings Park
  • Woburn, MA 01801
  • United States
+1 (781)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 68 Cummings Park
  • Woburn, MA 01801
  • United States
+1 (781)

Minerva Biotechnologies Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Minerva Biotechnologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC 05-Dec-2023 $4.51M Completed Clinical Trials - Phase 1
9. Later Stage VC 04-Jan-2023 Completed Clinical Trials - Phase 1
8. Later Stage VC 30-Oct-2019 Completed Clinical Trials - Phase 1
7. Later Stage VC 02-Oct-2018 Completed Clinical Trials - Phase 1
6. Later Stage VC 24-Oct-2014 Completed Clinical Trials - Phase 1
5. Grant 10-Jun-2014 Completed Clinical Trials - Phase 1
4. Later Stage VC 16-Nov-2010 Completed Clinical Trials - Phase 1
3. Seed Round Completed Clinical Trials - Phase 1
2. Angel (individual) 22-Nov-2006 $478K $478K Completed Clinical Trials - Phase 1
1. Accelerator/Incubator 01-Jan-2004 Completed Clinical Trials - Phase 1
To view Minerva Biotechnologies’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Minerva Biotechnologies Patents

Minerva Biotechnologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026206772-A1 Compositions and methods for the treatment of muc1* positive heterogeneous cancers Pending 24-Mar-2025
WO-2026050183-A1 Bacterial nme7 orthologs and uses thereof Pending 27-Aug-2024
AU-2024357558-A1 Anti-muc1* antibody drug complexes and uses thereof Pending 11-Oct-2023
EP-4587063-A1 Anti-muc1* antibody drug complexes and uses thereof Pending 11-Oct-2023
US-20250121088-A1 Anti-muc1* antibody drug complexes and uses thereof Inactive 11-Oct-2023 A61K47/6851
To view Minerva Biotechnologies’s complete patent history, request access »

Minerva Biotechnologies Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Minerva Biotechnologies Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
National Institute Of Allergy and Infectious Diseases Government
Angel (individual) Minority
Springboard Enterprises Accelerator/Incubator
To view Minerva Biotechnologies’s complete investors history, request access »

Minerva Biotechnologies FAQs

  • When was Minerva Biotechnologies founded?

    Minerva Biotechnologies was founded in 1999.

  • Where is Minerva Biotechnologies headquartered?

    Minerva Biotechnologies is headquartered in Woburn, MA.

  • What is the size of Minerva Biotechnologies?

    Minerva Biotechnologies has 17 total employees.

  • What industry is Minerva Biotechnologies in?

    Minerva Biotechnologies’s primary industry is Drug Discovery.

  • Is Minerva Biotechnologies a private or public company?

    Minerva Biotechnologies is a Private company.

  • What is Minerva Biotechnologies’s current revenue?

    The current revenue for Minerva Biotechnologies is .

  • How much funding has Minerva Biotechnologies raised over time?

    Minerva Biotechnologies has raised $60.2M.

  • Who are Minerva Biotechnologies’s investors?

    National Institute Of Allergy and Infectious Diseases, , and Springboard Enterprises have invested in Minerva Biotechnologies.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process